J&J reports ≥72% PASI 90 at Week 112
Johnson & Johnson (JNJ) reported two-year Phase 3 ICONIC-LEAD data for ICOTYDE, showing 72% of patients achieved PASI 90 at Week 112. 70% had clear or almost clear skin, and 78% sustained itch improvement. Safety findings were consistent with the established profile. ICOTYDE is approved in the U.S., Europe, Japan, and China for plaque psoriasis.
How this was made
The 30-second read
Why it matters
The trial confirms sustained high response rates through Week 112, reinforcing the drug's market position.
Market read
First disclosure of long‑term Phase 3 efficacy data for a major pharma product; likely to influence JNJ stock and dermatology peers.
What to watch
Long‑term reimbursement negotiations and competitive pipeline could temper the upside.
Background
J&J's ICOTYDE is already approved in major markets; the new long‑term efficacy data extends the label's value proposition.
Ticker impact
Johnson & Johnson reported Phase 3 ICONIC-LEAD trial data showing ≥72% of ICOTYDE‑treated patients achieved PASI 90 at Week 112.
likely upward pressure as investors price in the robust efficacy data
Phase 3 data for a marketed psoriasis drug is material for a large‑cap pharma; no prior public disclosure of these numbers.
Market effects
May boost confidence in dermatology pipelines and could lift peer psoriasis drug stocks.
U.S. and European markets may see modest gains in pharma indices.
Global investors tracking J&J and biotech trial outcomes will note the data.
Counterpoint
If safety concerns emerge later or market expectations were already high, the data may be already priced in.
Key entities
- companyJohnson & Johnson
Pharmaceutical giant reporting the trial results.
- productICOTYDE
J&J's psoriasis treatment under study.
